Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I thought this would be untradeable...
Just about every one of the IPO public investors redeemed their shares, leaving the founders and a few other service providers and insiders only. The redemption took just about all of the cash out of the treasury, so ANEW is starting out cashless.
On the LEAS side, the CEO controls the vote, and it is likely he’s going to mathematically do the RS he’s said all along he wants to do and award 99% of those RWOD shares to the preferred shareholders. He’s already taking 1.4M of those shares for himself.
They bought 1000 shares for $0.20 cents a share! Crazy
On the expert market, the stock can trade, but quotes of the bid and ask cannot be made public, shareholders/investors are flying blind. That’s why volume essentially goes to zero.
$LEAS When stocks go to the Expert market they are not available for trade on the Open Market...but can be bought and sold by marketers and brokers and they usually shred the price.
I do not believe this will have any affect on the Merger or the share conversion.
$LEAS $RWOD $WENA
LEAS remains on Scam Alert!
Everything looks to be on course.
No new PRs or Filings...but no red flags either.
$LEAS $RWOD $WENA
when will it release is the magic question
$LEAS $RWOD its happening
"When a SPAC merges, SPAC shareholders must believe they will receive about $10 per share in value to justify giving up their option to redeem at about $10. Target shareholders, however, will not agree to a merger unless they receive shares in the post-merger company at least equal to their estimation of the pre-merger value of their shares. Therefore, if target shareholders value SPAC shares only at their cash value, and negotiate a deal based on that value, SPAC shareholders will see their shares fall in price following the merger. For example, for the median SPAC with $6.67 in cash per share before the merger, shares would drop to $6.67 after the merger. This would mean the target has gotten an even deal and the SPAC shareholders have borne the cost of the SPAC’s dilution. If both target and SPAC shareholders are to break even or come out ahead, the merger must create sufficient surplus to fill the hole created by the SPAC’s dilution."...
I know but I see it on think or swim :o)
It’s expert market. There is no level 2, no quotations, bid, ask, not allowed.
so is this going to trade under Rwod symbol first or wena ?...
Sounds like we got rug pulled…. No filing either
really ,so you like wena :o)
+>>>LEAS - Yippie Yo Ki Yay!
CC
That is good.Keep my fingers crossed for all.
Another trader comment: Retransmit
i called my fidelity.....they aint no shit ....lolol told me check news and broadcasting.....I still BULLISH AS ALL HELL
Love to see some movement on this.
I thought we were going to be WENA but either way I'm excited to see this play out.
I just got of the phone with Schwab and the reason for the drop is that all LEAS shares are being “phased out” to become RWOD! It will not be long now. Congrats longs!
Probably not as it would be completely stopped.Someone is trading..
Sure seems like it
You all got fucked deep and Joseph Sinkule thanks you very much !!!! ......LOOOOOOOOL !!!
.0001 wow some of the bashers were right.. wow did we get fucked Or what
Some other traders are saying that their stocks LEAS are been transfer. How can we know that?
+>>>LEAS - Yikers. Chin Up Champ.
Better days ahead?
CC
Just dropped to $0.0001 this is the beginning of the transfer to NASDAQ
We are waiting for RWOD to fall below 1 dollar.Maybe 3 dollars would be enough.
What was the god damn point of approving merger when in the end it just went to em.. cant they just end it here and not do anything from this point on?
Theres not much to talk about since the stocks in em but yes i would like to know as well the timeline.. june latest?
Just here waiting. Bought 200 shares of RWOD
Patiently waiting...
Where is everyone? Just in waiting period? Does any have an idea of a normal timing on the process to get to NASDAQ?
tell us what you know so far :o)
You're probably right
It’s not.
Just some random dude posting who played a lawyer in his school play once.
Harmless but sort of sad that he hasn’t found happiness in life…
Where do you see that in the sec fillings?
+>>>>LEAS - Up Up and Away!!!!
Weeeeeeeee
CC
Merger Approved by all concerned parties.
Done Deal!!
$LEAS becoming $WENA
OTC has no hold on $WENA
$LEAS on the Expert becomes mute!
Looks all good to me👍
$LEAS RIGHT NOW WE MAY BE ON THE EM BUT…VERY SOON IT WILL BE ON NASDAQ AS NEW TICKER: WENA!!! 🐂-ISH!!!
JUST WAIT FOR IT…
So will LEAS be in the Expert Market for at least 6 months or what?
$LEAS people still here believing their $LEAS shares are worth anything! Well you’ll soon find out…
Medical product development and commercialization. The Company recently acquired five generic oncology drugs approved and manufactured in Germany and they plan to gain approval for these drugs in the US in 2023. The Company is preparing for a pivotal Phase 3 study of an anti-cancer antibody product that is highly similar to Genentech/Roche's brand name Avastin (bevacizumab), the Company has licensed a needle-free jet injector for drug delivery, and the Company is in the pre-clinical stages of development of a gene therapy product candidate based on the delivery of a human alpha-Klotho gene and protein to prevent and/or treat neurodegenerative diseases such as Alzheimer's and Lou Gehrig's disease (ALS). Other product candidates will stem from these platform technologies of pharmaceuticals, biologics, and gene therapy.
The Company's medical R&D facilities are in the U.S. (near the University of Nebraska Medical Center, Omaha, Nebraska) and in Barcelona, Spain (Autonomous Universitat de Barcelona). Each R&D facility is comprised of over 4,000 sq ft of R&D and office space, currently leased and equipped with research equipment, incubators, tissue culture facilities for production of plasmid DNA, HEPA-filtered hoods for aseptic handling, and testing equipment (PCR, spectrophotometers, microscopes, etc). The generic oncology drugs are manufactured in Germany. With future funding, the Company plans to acquire or build a GMP manufacturing facility to supply novel plasmid DNA ("transgenes") to be used in gene therapy programs, to provide contract manufacturing revenue, and for commercial product manufacturing.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |